Presence of human T lymphotropic virus types I and II in Ghana, west Africa.
Identifieur interne : 000736 ( PubMed/Corpus ); précédent : 000735; suivant : 000737Presence of human T lymphotropic virus types I and II in Ghana, west Africa.
Auteurs : R B Lal ; S M Owen ; J. Mingle ; P H Levine ; A. MannsSource :
- AIDS research and human retroviruses [ 0889-2229 ] ; 1994.
English descriptors
- KwdEn :
- Antibodies, Viral (immunology), Child, Female, Ghana (epidemiology), HTLV-I Infections (epidemiology), HTLV-I Infections (virology), HTLV-II Infections (epidemiology), HTLV-II Infections (virology), Human T-lymphotropic virus 1 (isolation & purification), Human T-lymphotropic virus 2 (isolation & purification), Humans, Pregnancy, Prevalence, Registries, Risk Factors, Seroepidemiologic Studies.
- MESH :
- chemical , immunology : Antibodies, Viral.
- geographic , epidemiology : Ghana.
- epidemiology : HTLV-I Infections, HTLV-II Infections.
- isolation & purification : Human T-lymphotropic virus 1, Human T-lymphotropic virus 2.
- virology : HTLV-I Infections, HTLV-II Infections.
- Child, Female, Humans, Pregnancy, Prevalence, Registries, Risk Factors, Seroepidemiologic Studies.
Abstract
Until recently, HTLV-I was considered to be an Old World virus and HTLV-II was thought to be endemic in the Americas. However, the presence of HTLV-II among Pygmies and other populations of Africa has raised doubts as to whether HTLV-II is primarily a New World virus. The large serosurveys conducted in the urban and rural areas of southern Ghana have identified a 1-2% prevalence for HTLV-I/II. To define the HTLV type, we have used a Western blot assay (HTLV-2.3 blot) that allows simultaneous confirmation and differentiation between HTLVs. Samples (n = 139) were chosen on the basis of previous reactivity with either an enzyme immune assay or r21e-spiked WB results. The WB 2.3 analysis of these specimens identified 55 (40%) to be HTLV positive, 70 (50%) to be HTLV indeterminant, and 14 (10%) to be HTLV negative for HTLV. HTLV seroindeterminant patterns ranged from both gag and env (14 were r21+, p24+, and/or p19+ [all were RIPA negative]) to gag only (21 were p24+/p19+, 16 were p19+, and 7 were p24+), and env only (8 were r21+ and 4 were rgp46+) reactivities. Of the 55 HTLV-positive specimens, 41 were typed as HTLV-I, 9 were HTLV-II, and 5 could not be typed (HTLV-I/II). Of the nine HTLV-II-positive specimens, three were from patients with Burkitt's lymphoma and six were from healthy individuals (two pregnant women) with no obvious risk factors for HTLV-II.(ABSTRACT TRUNCATED AT 250 WORDS)
DOI: 10.1089/aid.1994.10.1747
PubMed: 7888235
Links to Exploration step
pubmed:7888235Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Presence of human T lymphotropic virus types I and II in Ghana, west Africa.</title>
<author><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R B" last="Lal">R B Lal</name>
<affiliation><nlm:affiliation>Retrovirus Diseases Branch, National Center for Infectious Disease, CDC, Atlanta, Georgia 30333.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Owen, S M" sort="Owen, S M" uniqKey="Owen S" first="S M" last="Owen">S M Owen</name>
</author>
<author><name sortKey="Mingle, J" sort="Mingle, J" uniqKey="Mingle J" first="J" last="Mingle">J. Mingle</name>
</author>
<author><name sortKey="Levine, P H" sort="Levine, P H" uniqKey="Levine P" first="P H" last="Levine">P H Levine</name>
</author>
<author><name sortKey="Manns, A" sort="Manns, A" uniqKey="Manns A" first="A" last="Manns">A. Manns</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1994">1994</date>
<idno type="RBID">pubmed:7888235</idno>
<idno type="pmid">7888235</idno>
<idno type="doi">10.1089/aid.1994.10.1747</idno>
<idno type="wicri:Area/PubMed/Corpus">000736</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000736</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Presence of human T lymphotropic virus types I and II in Ghana, west Africa.</title>
<author><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R B" last="Lal">R B Lal</name>
<affiliation><nlm:affiliation>Retrovirus Diseases Branch, National Center for Infectious Disease, CDC, Atlanta, Georgia 30333.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Owen, S M" sort="Owen, S M" uniqKey="Owen S" first="S M" last="Owen">S M Owen</name>
</author>
<author><name sortKey="Mingle, J" sort="Mingle, J" uniqKey="Mingle J" first="J" last="Mingle">J. Mingle</name>
</author>
<author><name sortKey="Levine, P H" sort="Levine, P H" uniqKey="Levine P" first="P H" last="Levine">P H Levine</name>
</author>
<author><name sortKey="Manns, A" sort="Manns, A" uniqKey="Manns A" first="A" last="Manns">A. Manns</name>
</author>
</analytic>
<series><title level="j">AIDS research and human retroviruses</title>
<idno type="ISSN">0889-2229</idno>
<imprint><date when="1994" type="published">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (immunology)</term>
<term>Child</term>
<term>Female</term>
<term>Ghana (epidemiology)</term>
<term>HTLV-I Infections (epidemiology)</term>
<term>HTLV-I Infections (virology)</term>
<term>HTLV-II Infections (epidemiology)</term>
<term>HTLV-II Infections (virology)</term>
<term>Human T-lymphotropic virus 1 (isolation & purification)</term>
<term>Human T-lymphotropic virus 2 (isolation & purification)</term>
<term>Humans</term>
<term>Pregnancy</term>
<term>Prevalence</term>
<term>Registries</term>
<term>Risk Factors</term>
<term>Seroepidemiologic Studies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ghana</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HTLV-I Infections</term>
<term>HTLV-II Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Human T-lymphotropic virus 1</term>
<term>Human T-lymphotropic virus 2</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HTLV-I Infections</term>
<term>HTLV-II Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Child</term>
<term>Female</term>
<term>Humans</term>
<term>Pregnancy</term>
<term>Prevalence</term>
<term>Registries</term>
<term>Risk Factors</term>
<term>Seroepidemiologic Studies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Until recently, HTLV-I was considered to be an Old World virus and HTLV-II was thought to be endemic in the Americas. However, the presence of HTLV-II among Pygmies and other populations of Africa has raised doubts as to whether HTLV-II is primarily a New World virus. The large serosurveys conducted in the urban and rural areas of southern Ghana have identified a 1-2% prevalence for HTLV-I/II. To define the HTLV type, we have used a Western blot assay (HTLV-2.3 blot) that allows simultaneous confirmation and differentiation between HTLVs. Samples (n = 139) were chosen on the basis of previous reactivity with either an enzyme immune assay or r21e-spiked WB results. The WB 2.3 analysis of these specimens identified 55 (40%) to be HTLV positive, 70 (50%) to be HTLV indeterminant, and 14 (10%) to be HTLV negative for HTLV. HTLV seroindeterminant patterns ranged from both gag and env (14 were r21+, p24+, and/or p19+ [all were RIPA negative]) to gag only (21 were p24+/p19+, 16 were p19+, and 7 were p24+), and env only (8 were r21+ and 4 were rgp46+) reactivities. Of the 55 HTLV-positive specimens, 41 were typed as HTLV-I, 9 were HTLV-II, and 5 could not be typed (HTLV-I/II). Of the nine HTLV-II-positive specimens, three were from patients with Burkitt's lymphoma and six were from healthy individuals (two pregnant women) with no obvious risk factors for HTLV-II.(ABSTRACT TRUNCATED AT 250 WORDS)</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7888235</PMID>
<DateCreated><Year>1995</Year>
<Month>04</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted><Year>1995</Year>
<Month>04</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0889-2229</ISSN>
<JournalIssue CitedMedium="Print"><Volume>10</Volume>
<Issue>12</Issue>
<PubDate><Year>1994</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>AIDS research and human retroviruses</Title>
<ISOAbbreviation>AIDS Res. Hum. Retroviruses</ISOAbbreviation>
</Journal>
<ArticleTitle>Presence of human T lymphotropic virus types I and II in Ghana, west Africa.</ArticleTitle>
<Pagination><MedlinePgn>1747-50</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Until recently, HTLV-I was considered to be an Old World virus and HTLV-II was thought to be endemic in the Americas. However, the presence of HTLV-II among Pygmies and other populations of Africa has raised doubts as to whether HTLV-II is primarily a New World virus. The large serosurveys conducted in the urban and rural areas of southern Ghana have identified a 1-2% prevalence for HTLV-I/II. To define the HTLV type, we have used a Western blot assay (HTLV-2.3 blot) that allows simultaneous confirmation and differentiation between HTLVs. Samples (n = 139) were chosen on the basis of previous reactivity with either an enzyme immune assay or r21e-spiked WB results. The WB 2.3 analysis of these specimens identified 55 (40%) to be HTLV positive, 70 (50%) to be HTLV indeterminant, and 14 (10%) to be HTLV negative for HTLV. HTLV seroindeterminant patterns ranged from both gag and env (14 were r21+, p24+, and/or p19+ [all were RIPA negative]) to gag only (21 were p24+/p19+, 16 were p19+, and 7 were p24+), and env only (8 were r21+ and 4 were rgp46+) reactivities. Of the 55 HTLV-positive specimens, 41 were typed as HTLV-I, 9 were HTLV-II, and 5 could not be typed (HTLV-I/II). Of the nine HTLV-II-positive specimens, three were from patients with Burkitt's lymphoma and six were from healthy individuals (two pregnant women) with no obvious risk factors for HTLV-II.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lal</LastName>
<ForeName>R B</ForeName>
<Initials>RB</Initials>
<AffiliationInfo><Affiliation>Retrovirus Diseases Branch, National Center for Infectious Disease, CDC, Atlanta, Georgia 30333.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Owen</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mingle</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Levine</LastName>
<ForeName>P H</ForeName>
<Initials>PH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Manns</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>AIDS Res Hum Retroviruses</MedlineTA>
<NlmUniqueID>8709376</NlmUniqueID>
<ISSNLinking>0889-2229</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015490" MajorTopicYN="N">HTLV-I Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015491" MajorTopicYN="N">HTLV-II Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015368" MajorTopicYN="N">Human T-lymphotropic virus 1</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015367" MajorTopicYN="N">Human T-lymphotropic virus 2</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year>
<Month>12</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1994</Year>
<Month>12</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1994</Year>
<Month>12</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">7888235</ArticleId>
<ArticleId IdType="doi">10.1089/aid.1994.10.1747</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000736 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000736 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaGhanaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:7888235 |texte= Presence of human T lymphotropic virus types I and II in Ghana, west Africa. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7888235" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SidaGhanaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |